RxDoctor Payments Data

Randy Barnes, MD

Undersea and Hyperbaric Medicine · Meridian, IDNPI 1295811867

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.

$2,168in general payments, 2019–2025

Across 36 payments — averaging $60.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$372
  • Reapplix Inc.$264
  • Smith+Nephew$260
  • Acera Surgical, Inc.$206
  • Molnlycke Health Care US, LLC$175
  • KCI USA, Inc.$134
  • plus $757 from 10 others
$7,075in research payments, 2019–2025

Across 3 payments — averaging $2358.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$7K

What the payments were for

  • Food & beverage$2,168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few undersea and hyperbaric medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$64,894
Medicare patients
243
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate101$1,476
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav43$587
Nystatin20$586
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$501
Clindamycin Hcl15$385
Ciprofloxacin Hcl32$289
Mupirocin15$123

Paid to pharmacies, not to this prescriber.

Other undersea and hyperbaric medicine in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →